AR053652A1 - Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas - Google Patents

Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas

Info

Publication number
AR053652A1
AR053652A1 ARP050104664A ARP050104664A AR053652A1 AR 053652 A1 AR053652 A1 AR 053652A1 AR P050104664 A ARP050104664 A AR P050104664A AR P050104664 A ARP050104664 A AR P050104664A AR 053652 A1 AR053652 A1 AR 053652A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
substituted
heteroaryl
alkoxy
Prior art date
Application number
ARP050104664A
Other languages
English (en)
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of AR053652A1 publication Critical patent/AR053652A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Composiciones farmacéuticas que comprenden dichos compuestos. Reivindicacion 1: Un compuesto de la formula (1), en la cual: U, V y W son independientemente seleccionados entre CR5 y N, donde R5 es seleccionado entre hidrogeno y alquilo C1-6; Q es seleccionado entre NR5, NNR5 y CR5, donde R5 es seleccionado entre hidrogeno y alquilo C1-6; L1 es seleccionado entre -NR5C(O)-, -NR5C(O)NR5-, -C(O)NR5-, -NR5- y heteroarilo C5-10; donde R5 es seleccionado entre hidrogeno y alquilo C1-6; L2 es seleccionado entre un enlace, -O-, -NR5C(O)-, -NR5C(O)NR5-, -C(O)NR5- y -NR5-, donde R5 es seleccionado entre hidrogeno y alquilo C1-6; n es seleccionado entre 0 y 1; m es seleccionado entre 0, 1, 2, 3 y 4; R1 es seleccionado entre arilo C6-10, heteroarilo C5-10, cicloalquilo C3-12 y heterocicloalquilo C3-8; donde cualquier arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R1 está optativamente sustituido con uno a tres radicales independientemente seleccionados entre halo, amino, nitro, ciano, alquilo C1-6, alquilo C1-6 sustituido con halo, alcoxi C1-6, alcoxi C1-6 sustituido con halo, arilC6-10-alquiloC0-4, heteroarilC5-10-alquiloC0-4, cicloalquilC3-12-alquiloC0-4 y heterocicloalquilC3-8-alquiloC0-4, donde un metileno de cualquiera de los grupos alquilo puede ser optativamente reemplazado por oxígeno; donde cualquier sustituyente arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R1 puede ser optativamente sustituido con 1 a 3 radicales independientemente seleccionados entre alquilo C1-6, alcoxi C1-6, alquilo C1-6 sustituido con halo, alcoxi C1-6 sustituido con halo y alquilo C1-6 sustituido con hidroxi; R2 es seleccionado entre halo, amino, nitro, ciano, alquilo C1-6, alquilo C1-6 sustituido con halo, alcoxi C1-6, alcoxi C1-6 sustituido con halo, aril-C6-10- alquiloC0-4, cicloalquilC3-12-alquiloC0-4 y heteroarilC5-10-alquiloC0-4; donde cualquier arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R2 está optativamente sustituido con uno o tres radicales independientemente seleccionados entre halo, amino, nitro, ciano, alquilo C1-6, alcoxi C1-6, alquilo C1-6 sustituido con halo y alcoxi C1-6 sustituido con halo; R3 es seleccionado entre hidrogeno y alquilo C1-6; y R4 es seleccionado entre hidrogeno, -XR6, -XNR5XR6, -XOXR6 y -XNR5XR5R6, donde cada X es independientemente seleccionado entre un enlace y alquileno C1-4 donde cualquier alquileno de X puede ser optativamente sustituido con hidroxi, R5 es seleccionado entre hidrogeno y alquilo C1-6; R6 es seleccionado entre arilo C6-10, heteroarilo C5-10, cicloalquilo C3-12 y heterocicloalquilo C3-8, donde cualquier arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R6 puede ser optativamente sustituido con 1 a 3 radicales independientemente seleccionados entre alquilo C1-6, hidroxi, ciano, -NR5S(O)0-2R5, -S(O)0-2NR5R5, -NR5S(O)0-2NR5R5, -C(O) NR5XNR5R5, -XNR5XNR5R5, -C(O)R7, -C(O)NR5XOR5, -C(O)NR5R5, -C(O)NR5R7, -C(O)NR5XR7 y -XC(O)OR5; donde cada X es independientemente seleccionado entre un enlace y alquileno C1-4 donde cualquier alquileno de X puede ser optativamente sustituido con hidroxi, donde cada R5 es seleccionado entre hidrogeno y alquilo C1-6 y R7 es seleccionado entre heteroarilC5-10- alquiloC0-4 y heterocicloalquilC3-10-alquiloC0-4; donde cualquier heteroarilo o heterocicloalquilo de R7 está optativamente sustituido con un radical seleccionado del grupo constituido por dietil-amino-etilo, dimetil-amino, amino, alquilo C1-6, pirimidinilo, pirazinilo, alquilo C1-6 sustituido con halo y -C(O)OR5; así como las sales, hidratos, solvatos e isomero farmacéuticamente aceptables del mismo.
ARP050104664A 2004-11-09 2005-11-07 Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas AR053652A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62678504P 2004-11-09 2004-11-09
US70964805P 2005-08-19 2005-08-19

Publications (1)

Publication Number Publication Date
AR053652A1 true AR053652A1 (es) 2007-05-16

Family

ID=36337126

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104664A AR053652A1 (es) 2004-11-09 2005-11-07 Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas

Country Status (17)

Country Link
US (1) US8101608B2 (es)
EP (1) EP1814545A4 (es)
JP (1) JP4917041B2 (es)
KR (1) KR20070084066A (es)
AR (1) AR053652A1 (es)
AU (1) AU2005304719B2 (es)
BR (1) BRPI0517968A (es)
CA (1) CA2583737C (es)
GT (1) GT200500321A (es)
IL (1) IL182687A0 (es)
MA (1) MA29216B1 (es)
MX (1) MX2007005547A (es)
NO (1) NO20072887L (es)
RU (1) RU2406725C2 (es)
TN (1) TNSN07176A1 (es)
TW (1) TW200631577A (es)
WO (1) WO2006052936A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
JP4728340B2 (ja) 2004-10-25 2011-07-20 リガンド・ファーマシューティカルズ・インコーポレイテッド トロンボポエチン活性を変調する化合物および変調方法
CA2602453A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Kinase inhibitors
EP1902025A1 (en) 2005-07-13 2008-03-26 Allergan, Inc. Kinase inhibitors
US7749530B2 (en) 2005-07-13 2010-07-06 Allergan, Inc. Kinase inhibitors
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
WO2008022013A1 (en) * 2006-08-11 2008-02-21 Allergan, Inc. Kinase inhibitors
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
ES2565683T3 (es) 2006-09-15 2016-04-06 Xcovery, Inc. Compuestos inhibidores de quinasa
CN101522026A (zh) * 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
GEP20135925B (en) 2007-03-14 2013-10-10 Exelixis Patent Co Llc Inhibitors of hedgehog pathway
CA2960659C (en) 2007-11-09 2021-07-13 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
CL2009000400A1 (es) * 2008-02-22 2010-09-10 Irm Llc Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras.
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
JP2011520809A (ja) * 2008-05-05 2011-07-21 アムジエン・インコーポレーテツド γセクレターゼモジュレーターとしての尿素化合物
WO2009139834A1 (en) * 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EA029131B1 (ru) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CN102115472B (zh) * 2010-01-04 2013-12-04 深圳市天和医药科技开发有限公司 3-(2-吡咯亚甲基)氮杂吲哚啉-2-酮衍生物及其制法与应用
GB201014374D0 (en) * 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
WO2012151561A1 (en) 2011-05-04 2012-11-08 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2838538B1 (en) * 2012-04-20 2017-03-15 Annji Pharmaceutical Co., Ltd. Cyclopropanecarboxylate esters of purine analogues
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CA2879542A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
WO2014066840A1 (en) * 2012-10-26 2014-05-01 Regents Of The University Of Minnesota Aurora kinase inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US10487054B2 (en) 2017-04-21 2019-11-26 Regents Of The University Of Minnesota Therapeutic compounds
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
CN114853735B (zh) * 2022-07-06 2022-10-21 北京鑫开元医药科技有限公司 靶向泛素化降解trk的化合物及其制备方法、组合物和用途
CN114853736B (zh) * 2022-07-06 2022-10-21 北京鑫开元医药科技有限公司 具有trk抑制活性的化合物、制备方法、组合物及其用途
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024054793A1 (en) 2022-09-09 2024-03-14 University Of Rochester Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
EP1066257A2 (en) * 1998-03-26 2001-01-10 Sugen, Inc. Heterocylic classes of compounds for the modulating tyrosine protein kinase
PT1082302E (pt) * 1998-05-28 2004-04-30 Biogen Inc Um inibidor de amt-4: omepupa-v
TR200003514T2 (tr) 1998-05-29 2002-05-21 Sugen Inc. Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
AU5468499A (en) * 1998-08-04 2000-02-28 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
ME00415B (me) 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
AU2001268154A1 (en) * 2000-06-02 2001-12-17 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
AU2003302665B2 (en) 2002-11-15 2009-12-24 Symphony Evolution, Inc. Kinase modulators

Also Published As

Publication number Publication date
MX2007005547A (es) 2007-07-05
GT200500321A (es) 2006-09-04
RU2406725C2 (ru) 2010-12-20
AU2005304719B2 (en) 2009-07-23
WO2006052936A3 (en) 2006-10-26
JP2008519762A (ja) 2008-06-12
TW200631577A (en) 2006-09-16
CA2583737C (en) 2011-09-20
EP1814545A4 (en) 2009-06-10
RU2007121505A (ru) 2008-12-20
WO2006052936A2 (en) 2006-05-18
TNSN07176A1 (en) 2008-11-21
CA2583737A1 (en) 2006-05-18
KR20070084066A (ko) 2007-08-24
US20080221192A1 (en) 2008-09-11
NO20072887L (no) 2007-08-03
US8101608B2 (en) 2012-01-24
JP4917041B2 (ja) 2012-04-18
BRPI0517968A (pt) 2008-10-21
IL182687A0 (en) 2007-09-20
AU2005304719A1 (en) 2006-05-18
MA29216B1 (fr) 2008-02-01
EP1814545A2 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
CO5680403A2 (es) Antagonistas de mchr1r
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR050435A1 (es) DERIVADOS DE HIDROXIAMIDA, PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS.
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR070343A1 (es) Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica
AR049898A1 (es) Compuestos aminocarbonil fenilo sustituidos, composicion farmaceutica,uso y proceso para prepararlos
AR041260A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR037534A1 (es) Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
AR074817A1 (es) Dihidropiridona-amidas como moduladores de p2x7
AR054031A1 (es) Compuestos acilaminobiciclicos ligandos de receptores cannabinoides
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
AR045819A1 (es) Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos
CO5590916A2 (es) Dicetopiperacinas sustituidas como antagonistas de oxitocina
AR061185A1 (es) Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure